{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:28:27Z","timestamp":1791905307618,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,12,30]],"date-time":"2009-12-30T00:00:00Z","timestamp":1262131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00280-009-1226-z","type":"journal-article","created":{"date-parts":[[2009,12,29]],"date-time":"2009-12-29T14:24:33Z","timestamp":1262096673000},"page":"837-844","source":"Crossref","is-referenced-by-count":59,"title":["Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study"],"prefix":"10.1007","volume":"66","author":[{"given":"Salvatore Del","family":"Prete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Montella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Maiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Cennamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Montesarchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Piai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Febbraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovannella","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Guarrasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Mamone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"Savastano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Sabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Faiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,30]]},"reference":[{"issue":"3","key":"1226_CR1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14712590802680158","volume":"18","author":"R Addeo","year":"2009","unstructured":"Addeo R, Caraglia M, Del Prete S (2009) Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. Expert Opin Investig Drugs 18(3):373\u2013378 (7 Nov 2008, Naples, Italy)","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl 7","key":"1226_CR2","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mdl964","volume":"17","author":"M Caraglia","year":"2006","unstructured":"Caraglia M, Tassone P, Marra M et al (2006) Targeting Raf-kinase: molecular rationales and translational issues. Ann Oncol 17(Suppl 7):vii124\u2013vii127","journal-title":"Ann Oncol"},{"key":"1226_CR3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-007-0639-9","volume":"61","author":"CH Takimoto","year":"2008","unstructured":"Takimoto CH, Awada A (2008) Safety and anti-tumor activity of sorafenib (Nexavar\u00ae) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61:535\u2013548","journal-title":"Cancer Chemother Pharmacol"},{"issue":"359","key":"1226_CR4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"24","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 24(359):378\u2013390","journal-title":"N Engl J Med"},{"key":"1226_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334","journal-title":"Lancet Oncol"},{"key":"1226_CR6","doi-asserted-by":"crossref","first-page":"8093","DOI":"10.1200\/JCO.2004.00.1537","volume":"23","author":"MB Thomas","year":"2008","unstructured":"Thomas MB, Abbruzzese JL (2008) Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23:8093\u20138108","journal-title":"J Clin Oncol"},{"key":"1226_CR7","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/hep.22506","volume":"48","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312\u20131327","journal-title":"Hepatology"},{"key":"1226_CR8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Di Bisceglie A, Bruix J et al (2008) Design and end-points of clinical trials in HCC. J Natl Cancer Inst 100:698\u2013711","journal-title":"J Natl Cancer Inst"},{"key":"1226_CR9","first-page":"2S13","volume":"63","author":"L Buscail","year":"2002","unstructured":"Buscail L, Vernejoul F, Faure P, Torrisani J, Susini C (2002) Regulation of cell proliferation by somatostatin. Ann Endocrinol (Paris) 63:2S13\u20132S18","journal-title":"Ann Endocrinol (Paris)"},{"key":"1226_CR10","doi-asserted-by":"crossref","first-page":"R490","DOI":"10.1152\/ajpregu.00099.2008","volume":"295","author":"AL Hagemeister","year":"2008","unstructured":"Hagemeister AL, Sheridan MA (2008) Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways. Am J Physiol Regul Integr Comp Physiol 295:R490\u2013R497","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1226_CR11","first-page":"617","volume":"8","author":"M Zhao","year":"1993","unstructured":"Zhao M, Laissue JA, Zimmermann A (1993) \u201cNeuroendocrine\u201d differentiation in hepatocellular carcinomas (HCCs): immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade. Histol Histopathol 8:617\u2013626","journal-title":"Histol Histopathol"},{"key":"1226_CR12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gut.42.3.442","volume":"42","author":"E Kouroumalis","year":"1998","unstructured":"Kouroumalis E, Skordilis P, Thermos K et al (1998) Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 42:442\u2013447","journal-title":"Gut"},{"key":"1226_CR13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/gut.45.5.766","volume":"45","author":"JC Reubi","year":"1999","unstructured":"Reubi JC, Zimmermann A, Jonas S et al (1999) Regulatory peptide receptors in human hepatocellular carcinomas. Gut 45:766\u2013774","journal-title":"Gut"},{"key":"1226_CR14","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/gut.52.10.1531-a","volume":"52","author":"JT Siveke","year":"2003","unstructured":"Siveke JT, Herberhold C, Folwaczny C (2003) Complete regression of advanced HCC with long acting octreotide. Gut 52:1531","journal-title":"Gut"},{"key":"1226_CR15","first-page":"903","volume":"9","author":"DN Samonakis","year":"2002","unstructured":"Samonakis DN, Moschandreas J, Arnaoutis T et al (2002) Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 9:903\u2013907","journal-title":"Oncol Rep"},{"key":"1226_CR16","first-page":"1245","volume":"49","author":"D Dimitroulopoulos","year":"2002","unstructured":"Dimitroulopoulos D, Xinopoulos D, Tsamakidis K et al (2002) The role of Sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49:1245\u20131250","journal-title":"Hepatogastroenterology"},{"key":"1226_CR17","first-page":"1197","volume":"16","author":"M Raderer","year":"2000","unstructured":"Raderer M, Hejna MH, Muller C et al (2000) Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 16:1197\u20131201","journal-title":"Int J Oncol"},{"key":"1226_CR18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bjc.6603325","volume":"95","author":"J Cebon","year":"2006","unstructured":"Cebon J, Australasian Gastro-Intestinal Trials Group (AGITG) AG000IH Investigators (2006) Somatostatin receptor expression, tumor response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 95:853\u2013861","journal-title":"Br J Cancer"},{"key":"1226_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hep.21468","volume":"45","author":"G Becker","year":"2007","unstructured":"Becker G, Allgaier HP, Olschewski M et al (2007) HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45:9\u201315","journal-title":"Hepatology"},{"key":"1226_CR20","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s10620-007-0175-9","volume":"53","author":"DN Samonakis","year":"2008","unstructured":"Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA (2008) Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci 53:2359\u20132365","journal-title":"Dig Dis Sci"},{"key":"1226_CR21","first-page":"385","volume":"20","author":"L Montella","year":"2008","unstructured":"Montella L, Addeo R, Caraglia M et al (2008) Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience. Oncol Rep 20:385\u2013390","journal-title":"Oncol Rep"},{"key":"1226_CR22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Susan G, Arbuck SG et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1226_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"1226_CR24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"1226_CR25","first-page":"1676","volume":"5","author":"TWT Leung","year":"1999","unstructured":"Leung TWT, Patt YZ, Lau W et al (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676\u20131681","journal-title":"Clin Cancer Res"},{"key":"1226_CR26","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard J-Y, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293\u20134300","journal-title":"J Clin Oncol"},{"key":"1226_CR27","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1349-7006.2008.00837.x","volume":"99","author":"H Minami","year":"2008","unstructured":"Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K (2008) Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99:1492\u20131498","journal-title":"Cancer Sci"},{"key":"1226_CR28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","volume":"99","author":"J Furuse","year":"2008","unstructured":"Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159\u2013165","journal-title":"Cancer Sci"},{"key":"1226_CR29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426\u2013437","journal-title":"Oncologist"},{"key":"1226_CR30","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.1200\/jco.2007.25.18_suppl.3546","volume":"25","author":"SJ Faivre","year":"2007","unstructured":"Faivre SJ, Raymond E, Douillard J et al (2007) Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 25:149s (Suppl; abstr 3546)","journal-title":"J Clin Oncol"},{"key":"1226_CR31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cncr.23175","volume":"112","author":"AX Zhu","year":"2008","unstructured":"Zhu AX (2008) Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112:250\u2013259","journal-title":"Cancer"},{"key":"1226_CR32","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1200\/JCO.2005.14.696","volume":"23","author":"PA Philip","year":"2005","unstructured":"Philip PA, Mahoney MR, Allmer C et al (2005) Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657\u20136663","journal-title":"J Clin Oncol"},{"key":"1226_CR33","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.22886","volume":"110","author":"MB Thomas","year":"2007","unstructured":"Thomas MB, Chadha R, Glover K et al (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059\u20131066","journal-title":"Cancer"},{"key":"1226_CR34","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncr.24029","volume":"115","author":"T Yau","year":"2009","unstructured":"Yau T, Chan P, Ng KK et al (2009) Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115:428\u2013436","journal-title":"Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1226-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1226-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1226-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:24:18Z","timestamp":1711106658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1226-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,30]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1226-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,30]]}}}